Class summary at a glance.

Every drug in the Macrolide class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $5.3Mcombined across class
Total Rx claims: 11K3K unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Erythromycin Ethylsuccinate

Brand: E.E.S · 11K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2011-04-18

4 generic mfrs 0 plans require PA

Low NADAC$0.822

→

Avg plan cost$1.35

Part D spend $5.3M 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Erythromycin

Brand: ERY-TAB · — Part D claims (CY24) · First FDA approval: 1994-07-29

15 generic mfrs 0 plans require PA

Low NADAC$0.355

→

Avg plan cost$2.46

Part D spend — 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Erythromycin Topical Solution

— Part D claims (CY24) · First FDA approval: 2024-08-14

Brand-only (no generics)

Low NADAC$0.355

→

Avg plan cost$0.355

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Erythromycin and Benzoyl Peroxide

Brand: Benzamycin · — Part D claims (CY24) · First FDA approval: 1984-10-26

1 generic mfrs 0 plans require PA

Low NADAC$0.974

→

Avg plan cost$1.38

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.